Concert Genetics, Inc. Market Research Report

Background

Company Overview

Concert Genetics, Inc. is a healthcare technology company specializing in the digital infrastructure for genetic testing and precision medicine. Established in 2010 as NextGxDx, the company rebranded to Concert Genetics in 2017 to better reflect its mission of connecting all stakeholders in the genetic health ecosystem. The company is headquartered in Nashville, Tennessee, and serves a diverse clientele, including health plans, hospitals, health systems, clinicians, and laboratories.

Mission and Vision

Concert Genetics aims to advance precision medicine by providing reliable and efficient management of genetic testing. Its vision is to create a connected healthcare ecosystem that facilitates seamless collaboration among all stakeholders involved in genetic health.

Primary Area of Focus

The company's primary focus is on developing and offering a comprehensive software and managed services platform that addresses the complexities of genetic testing. This includes managing the entire lifecycle of genetic testing—from ordering and resulting to coding, coverage, and ensuring payment integrity.

Industry Significance

In the rapidly evolving field of precision medicine, Concert Genetics plays a pivotal role by streamlining genetic testing processes. Its solutions enhance the efficiency and accuracy of genetic test ordering, resulting, coding, coverage, and payment, thereby reducing administrative burdens and improving patient care.

Key Strategic Focus

Core Objectives

Automation of Genetic Test Processes: Implementing systems that automate the determination of coverage and reimbursement for genetic tests, thereby reducing manual interventions and errors.

Integration of Stakeholders: Facilitating seamless collaboration among health plans, laboratories, and healthcare providers to enhance the efficiency of genetic testing services.

Specific Areas of Specialization

Genetic Test Identification: Developing unique identifiers for over 160,000 genetic testing products to standardize and streamline the ordering and reimbursement processes.

Payment Integrity Solutions: Providing real-time claim editing capabilities to ensure accurate and timely reimbursement for genetic tests.

Key Technologies Utilized

Concert GTU® System: A proprietary genetic test identification system that assigns unique identifiers to genetic tests, facilitating accurate ordering and reimbursement.

Machine Learning Algorithms: Employed in real-time claim editing to enhance the accuracy and efficiency of payment processes.

Primary Markets Targeted

Health Plans: Assisting in the implementation of genetic testing and precision medicine strategies.

Laboratories: Collaborating to ensure accurate coding and coverage policies for genetic tests.

Healthcare Providers: Supporting clinicians in selecting and ordering appropriate genetic tests for patients.

Financials and Funding

Funding History

January 2018: Completed a growth capital financing round led by Deerfield Management, aimed at expanding its offerings in genetic testing management.

Total Funds Raised

Specific details regarding the total funds raised by Concert Genetics are not publicly disclosed.

Notable Investors

Deerfield Management: Led the growth capital financing round in January 2018.

Utilization of Capital

The funds have been utilized to enhance product offerings, support connectivity across the genetic health information network, and expand the company's impact in the industry.

Pipeline Development

Concert Genetics focuses on developing and enhancing its software and managed services platform rather than a traditional product pipeline. Key developments include:

Genetic Test Identification System: Launched a comprehensive system assigning unique identifiers to over 160,000 genetic testing products, facilitating automation in test ordering and reimbursement.

Preferred Laboratory Network: Established a network of genetic testing laboratories meeting rigorous quality, service, and billing integrity standards to streamline administrative coordination.

Technological Platform and Innovation

Proprietary Technologies

Concert GTU® System: A proprietary genetic test identification system that assigns unique identifiers to genetic tests, facilitating accurate ordering and reimbursement.

Significant Scientific Methods

Machine Learning Algorithms: Utilized in real-time claim editing to enhance the accuracy and efficiency of payment processes.

Leadership Team

Rob Metcalf: Chief Executive Officer (CEO)

Professional Background: Rob Metcalf has been leading Concert Genetics since 2016, focusing on advancing precision medicine through digital infrastructure.

Gillian Hooker, PhD, ScM, LCGC: Chief Scientific Officer (CSO)

Professional Background: Dr. Hooker is a board-certified genetic counselor and has served as the immediate Past President of the National Society of Genetic Counselors.

Competitor Profile

Market Insights and Dynamics

The genetic testing and precision medicine market is rapidly evolving, with increasing demand for efficient and accurate genetic testing solutions. Key trends include the integration of genetic testing into mainstream healthcare and the need for standardized processes to manage the complexity of genetic tests.

Competitor Analysis

Invitae Corporation: A leading medical genetics company offering a broad range of genetic tests and services.

Myriad Genetics, Inc.: Specializes in molecular diagnostics and precision medicine, providing genetic testing services across various medical specialties.

NeoGenomics Laboratories, Inc.: Focuses on cancer genetics diagnostic testing, offering a comprehensive suite of services for oncology patients.

Strategic Collaborations and Partnerships

The Burgess Group: Integrated Concert Genetics' real-time claim editing capabilities into the Burgess Source® claims payment automation platform to enhance payment integrity.

Preferred Laboratory Network: Established a network of genetic testing laboratories, including Invitae, PreventionGenetics, and GeneDx, to streamline administrative coordination and improve service quality.

Operational Insights

Concert Genetics differentiates itself by offering a comprehensive platform that addresses the entire lifecycle of genetic testing, from ordering to reimbursement. Its proprietary technologies, such as the Concert GTU® System and machine learning algorithms for claim editing, provide a competitive edge in the market.

Strategic Opportunities and Future Directions

The company is well-positioned to expand its market presence by leveraging its technological innovations and strategic partnerships. Future opportunities include further integration with healthcare providers and laboratories, expansion into new markets, and continuous enhancement of its platform to meet the evolving needs of precision medicine.